Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- AURA
- Price
- 5.74
- Stock movement up
- +0.26 (4.74%)
- Company name
- Aura Biosciences Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 364.51M
- Ent value
- 350.31M
- Price/Sales
- 294.43
- Price/Book
- 2.33
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- -27.62%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
AURA does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 294.43 |
| Price to Book | 2.33 |
| EV to Sales | 282.97 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 63.50M |
| EPS (TTM) | -1.61 |
| FCF per share (TTM) | -1.35 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 1.24M |
| Gross profit (TTM) | -1.18M |
| Operating income (TTM) | -113.36M |
| Net income (TTM) | -106.47M |
| EPS (TTM) | -1.61 |
| EPS (1y forward) | -1.86 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -95.48% |
| Operating margin (TTM) | -9156.79% |
| Profit margin (TTM) | -8599.84% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 47.55M |
| Net receivables | 0.00 |
| Total current assets | 170.12M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 25.70M |
| Total assets | 190.02M |
| Accounts payable | 1.89M |
| Short/Current long term debt | 17.75M |
| Total current liabilities | 18.82M |
| Total liabilities | 33.36M |
| Shareholder's equity | 156.67M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -88.22M |
| Capital expenditures (TTM) | 570.00K |
| Free cash flow (TTM) | -88.80M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -67.96% |
| Return on Assets | -56.03% |
| Return on Invested Capital | -66.59% |
| Cash Return on Invested Capital | -55.54% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 5.54 |
| Daily high | 5.83 |
| Daily low | 5.51 |
| Daily Volume | 250K |
| All-time high | 24.89 |
| 1y analyst estimate | 19.40 |
| Beta | 0.44 |
| EPS (TTM) | -1.61 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 31 Mar 2026 |
Downside potential
Loading...
Downside potential data
| AURA | S&P500 | |
| Current price drop from All-time high | -76.94% | -0.89% |
| Highest price drop | -80.31% | -19.00% |
| Date of highest drop | 14 May 2025 | 8 Apr 2025 |
| Avg drop from high | -72.04% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
364.51M
Marketcap category
Small-cap
Description
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer, as an alternative to bacillus calmette"guérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Employees
106
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page